Zura Bio (NASDAQ:ZURA) Research Coverage Started at Piper Sandler

Piper Sandler started coverage on shares of Zura Bio (NASDAQ:ZURA) in a report published on Friday morning, Marketbeat.com reports. The firm issued an overweight rating and a $26.00 price objective on the stock.

Separately, Oppenheimer restated an outperform rating and issued a $16.00 price target (down previously from $17.00) on shares of Zura Bio in a research report on Monday, April 1st. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of Buy and an average target price of $18.00.

Zura Bio Stock Performance

NASDAQ:ZURA opened at $4.62 on Friday. Zura Bio has a one year low of $2.00 and a one year high of $14.00. The business has a fifty day moving average price of $3.26 and a 200-day moving average price of $3.93.

Insiders Place Their Bets

In other Zura Bio news, Director Amit Munshi bought 159,744 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The shares were bought at an average price of $3.13 per share, with a total value of $499,998.72. Following the purchase, the director now owns 777,384 shares of the company’s stock, valued at $2,433,211.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders acquired 170,926 shares of company stock worth $534,998. Corporate insiders own 15.80% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

Institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC boosted its stake in Zura Bio by 66.3% during the third quarter. Armistice Capital LLC now owns 1,580,000 shares of the company’s stock valued at $10,428,000 after buying an additional 630,000 shares during the last quarter. Silverarc Capital Management LLC raised its holdings in shares of Zura Bio by 152.5% during the 3rd quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock worth $2,667,000 after acquiring an additional 244,040 shares in the last quarter. Lynx1 Capital Management LP bought a new position in shares of Zura Bio during the 3rd quarter valued at approximately $65,000. Raymond James & Associates grew its holdings in shares of Zura Bio by 14.0% in the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock valued at $511,000 after purchasing an additional 9,481 shares in the last quarter. Finally, Eisler Capital US LLC bought a new stake in Zura Bio in the third quarter worth $660,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.